Skip to content

LSD for addiction: all studies

Page 4 of 6: studies 31 to 40 of 58, newest first. Back to the LSD for addiction overview

Research

Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Journal of Xenobiotics February 7, 2022 Maurizio Coppola, Francesco Bevione, Raffaella Mondola 29 citations

Psychedelics extracted from plants have been used in religious, spiritual, and mystic practices for millennia. In 1957, Dr. Hofmann identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although there were limitations related to the scientific design of many studies, clinical observations performed during the 1950s and 1960s...

Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.

Current Topics in Behavioral Neurosciences 2022 Nathalie M Rieser, Marcus Herdener, Katrin H Preller

Substance use disorders (SUD) represent a significant public health issue with a high need for novel and efficacious treatment options. In light of this high unmet need, recent results reporting beneficial outcomes of psychedelic-assisted therapy in SUD are particularly relevant. However, several questions remain with regard to this treatment approach. The clinical mechanisms of action of...

Psychedelics and Hallucinogens in Psychiatry: Finding New PharmacologicalTargets

Current Topics in Medicinal Chemistry December 2, 2021 Teresa Reynolds de Sousa, João Rema, Sérgio Machado et al. 7 citations

Background: The therapeutic options for neurobehavioral disorders are still limited, and in many cases, they lack a satisfactory balance between efficacy and side effects. Objective: This work aims to review current evidence regarding the potential contribution of psychedelics and hallucinogens to the discovery of new drugs for treating different psychiatric disorders. Discussion:...

[Efficacy of psychedelics in psychiatry, a systematic review of the literature].

L'Encephale August 1, 2021 Lucie Berkovitch, Bruno Romeo, Laurent Karila et al. 25 citations

Psychedelics are powerful psychoactive substances. Natural psychedelics have been used for millennia by human civilizations, in particular in Latin America, while synthetic psychedelics were discovered in the 50s, giving rise to a lot of research before they were prohibited. More recently, their therapeutic properties have been studied especially to help patients with psychiatric conditions,...

MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers

Trials April 23, 2021 Robin J Murphy, Rachael Sumner, William Evans et al. 23 citations

BACKGROUND: Regular ingestion of sub-hallucinogenic doses of psychedelics, referred to as "microdosing", has gained increasing popularity and attention in the press and in online forums, with reported benefits across multiple cognitive and emotional domains. Rigorously controlled studies to date, however, have been limited in scope and have failed to produce results comparable to those reported...

Psychedelics and psychiatric disorders: A emerging role

European Psychiatry April 1, 2021 Clayton Peixoto, Fabiano Santos, Daianne Cardinalli Rêgo et al. 1 citation

Introduction Recently there has been renewal in interest of psychedelic research. Classic psychedelics such as lysergic acid diethylamide (LSD), psilocybin and mescaline act pharmacologically as agonists at the 5-HT2A receptor. The entactogens like methylenedioxymethamphetamine (MDMA), acts as a serotonin, dopamine and noradrenaline agonist. All of these drugs are potential candidates in the...

After more than sixty years we are still unclear whether LSD has a place in clinical psychiatry

Research in Psychotherapy Psychopathology Process and Outcome October 1, 2020 Arthur Saniotis 1 citation

Dear Editor, The use of the psychedelic Lysergic Acid Diethylamide (LSD) has again provoked scientific debate over its efficacy and safety. In the 1950s-1960s LSD was used in psychotherapy for treating depression, anxiety related to terminal cancer, addiction, and pain. (...)

Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse

Neuropsychopharmacology May 5, 2020 Marcus W. Meinhardt, Cansu Güngör, Ivan Skorodumov et al. 66 citations

For most psychiatric disorders, including alcohol use disorder (AUD), approved pharmacological treatments are limited in their effectiveness, and new drugs that can easily be translated into the clinic are needed. Currently, great hope lies in the potential of psychedelics to effectively treat AUD. The primary hypothesis is that a single session of psychedelic-guided psychotherapy can restore...

Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.

Psychopharmacology May 1, 2020 Toby Lea, Nicole Amada, Henrik Jungaberle et al.

The regular consumption of very small doses of psychedelic drugs (known as microdosing) has been a source of growing media and community attention in recent years. However, there is currently limited clinical and social research evidence on the potential role of microdosing as therapies for mental and substance use disorders. This paper examined subjective experiences of microdosing...

Psychedelics and dissociative substances

March 1, 2020 Adam Winstock, James W. Rucker 29 citations

Abstract Psychedelics and hallucinogens represent some of the most commonly used drugs in the world, with a history of use steeped in spirituality, counter-culture, and more recently latent therapeutic potential. Sharing a common mechanism of action at the 5-HT2a receptor, drugs such as lysergic acid diethylamide (LSD) and psilocybin, while they can rarely induce significant short-term...